Clinical and prognostic evaluation of patients admitted to the COVID-19 pandemic unit of the emergency department

Year 2021, Volume: 4 Issue: 6, 835 - 839, 24.09.2021

Şenay Öztürk Durmaz , Ayşenur Sümer Coşkun , Ata Nevzat Yalçın

https://doi.org/10.32322/jhsm.972723

Cited By: 8

Abstract

Objective: This study aimed to evaluate to prognosis of patients admitted to the COVID-19 isolation unit of the emergency department and present epidemiological data by examining their demographic, clinical, laboratory and lung tomography findings.
Material and Method: A total of 504 patients presenting with COVID-19 symptoms were randomly and retrospectively evaluated based on electronic records obtained from the hospital archive.
Results: Of the patients, 216 (42.9%) were female and 288 (57%) were male. The RT-PCR test was positive in 291 (57.7%) patients, and fever was the most common symptom in 280 (55.5%). A total of 133 patients (26.4%) were admitted to the inpatient ward. The WBC, Troponin-t, CRP, AST, ALT, LDH, D-dimer and ferritin levels were high and lymphocyte count was low in patients who were hospitalized. Sixty-one percent of the patients had a comorbid condition; 19% of had diabetes and 18.8% had hypertension as the most common underlying condition. Totally, 312 (61.9%) had favipiravir, 106 (21%) were favipiravir + hydroxychloroquine, 60 (11.9%) used hydroxychloroquine alone, 26 (5.2%) were followed up without treatment and to 147 of them, antibiotics were prescribed in addition to the medicine; 38.5% of the patients followed up in the intensive care unit were diabetic; 26 patients (5.2%) were followed up in the intensive care unit. The mortality rate was found to be 1.9%. At least one comorbid condition was present in all who were hospitalized and died in the intensive care unit.
Conclusion: The importance of a healthy diet and regular physical activity for metabolic conditions such as diabetes and hypertension as well as for fighting infections is well known. We consider that the mortality and morbidity rates due to the COVID-19 pandemic can be reduced by developing reliable and safe antiviral treatment options and implementing effective and fair vaccination policies.

Keywords

COVID-19, Epidemiology, Prognosis

References

• Hasöksüz M, Kiliç S, Saraç F. Coronaviruses and sars-cov-2. Turk J Med Sci 2020; 50: 549-56.
• Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 55: 105924.
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med 2020; 382: 1708-20.
• Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. Am J Roentgenol 2020; 215: 87-93.
• Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis. J Med Virol 2020; 92: 1518-24.
• Hao W, Li M. Clinical diagnostic value of CT imaging in COVID-19 with multiple negative RT-PCR testing. Travel Med Infect Dis 2020; 34: 101607.
• Wang S, Kang B, Ma J, et al. A deep learning algorithm using CT images to screen for corona virus disease (COVID-19). Eur Radiol 2021: 1-9.
• Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020; 55: 105955.
• COVID-19 Information Page. Access date: 11, 2020. Access: https://covid19.saglik.gov.tr/TR 66935/genelkoronavirus-tablosu.html
• British Society of Thoracic Imaging. Thoracic imaging in COVID-19 infection. Guidance for the reporting radiologist. Version 2. 16 March 2020 [Internet]. UK BSTI [Access 15 June 2020].https:\\www.bsti.org.uk\media\resources\files\BSTI_COVID-19_Radiology_Guidance_version_2_16.03.20.pdf.
• Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy 2020; 75: 1730-41.
• World Health Organization. (2020). Coronavirus disease 2019 (COVID-19): situation report, 60. https://www.who.int/health-topics/coronavirus#tab=- tab_3. Access date 01.07.2020.
• Karakoc ZC, Pinarbasi Simsek B, Asil R, et al. First wave in the COVID-19 pandemic: one center experience. Klimik J/Klimik Derg 202; 33: 3.
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020; 395: 1054-62.
• Elshafeey F, Magdi R, Hindi N, et al. A systematic scoping review of COVID‐19 during pregnancy and childbirth. Int J Gynecol Obstet 2020; 150: 47-52.
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama 2020; 323: 1061-9.
• Turkey Health Ministry (2020). General Directorate of Public Health, Covid-19 (SARS-CoV-2) guide (Scientific Committee Study). Access date:10 July 2020. Available from: https:\\hsgm.saglik.gov.tr\tr\covid19.
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama 2020; 323: 1239-42.
• Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Med 2006; 23: 623-8.
• Allard R, Leclerc P, Tremblay C, Tannenbaum TN. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care 2010; 33: 1491-3.
• Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. Jama 2020; 323: 1545-6.
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-71.
• Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antivir Res 2018; 153: 85-94.
• Turkey Health Ministry (2020). The current situation in Turkey. 2020. Available from https:\\saglik.gov.tr\Access date: June 1, 2020.
• World Health Organization. (2020). WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020.
• Eraksoy, H. COVID-19 Pandemic: Leaving First Four Months Behind/ COVID-19 Pandemic. KLIMIK J 2020; 33: 1-2.
• Genç A, Kurtaiş Aytür Y. Acute and Post-acute pulmonary rehabilitation in COVID-19 infection. COVID-19 Pandemisi ve Fiziksel Tıp ve Rehabilitasyon. 1st Edition. Ankara: Türkiye Klinikleri; 2020; 7-12.